109 related articles for article (PubMed ID: 22161982)
41. Platelet-derived growth factor C promotes revascularization in ischemic limbs of diabetic mice.
Moriya J; Wu X; Zavala-Solorio J; Ross J; Liang XH; Ferrara N
J Vasc Surg; 2014 May; 59(5):1402-9.e1-4. PubMed ID: 23856609
[TBL] [Abstract][Full Text] [Related]
42. Role of the VEGF/VEGFR axis in cancer biology and therapy.
Rapisarda A; Melillo G
Adv Cancer Res; 2012; 114():237-67. PubMed ID: 22588059
[TBL] [Abstract][Full Text] [Related]
43. Angiogenesis--a new target for future therapy.
Pandya NM; Dhalla NS; Santani DD
Vascul Pharmacol; 2006 May; 44(5):265-74. PubMed ID: 16545987
[TBL] [Abstract][Full Text] [Related]
44. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor.
Jain RK
Semin Oncol; 2002 Dec; 29(6 Suppl 16):3-9. PubMed ID: 12516032
[TBL] [Abstract][Full Text] [Related]
45. [The role of vascular endothelial growth factor in angiogenesis and diabetic retinopathy].
Valiatti FB; Crispim D; Benfica C; Valiatti BB; Kramer CK; Canani LH
Arq Bras Endocrinol Metabol; 2011 Mar; 55(2):106-13. PubMed ID: 21584427
[TBL] [Abstract][Full Text] [Related]
46. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
[TBL] [Abstract][Full Text] [Related]
47. Presence and regulation of endocrine gland vascular endothelial growth factor/prokineticin-1 and its receptors in ovarian cells.
Kisliouk T; Levy N; Hurwitz A; Meidan R
J Clin Endocrinol Metab; 2003 Aug; 88(8):3700-7. PubMed ID: 12915658
[TBL] [Abstract][Full Text] [Related]
48. KDR/Flk-1 is a major regulator of vascular endothelial growth factor-induced tumor development and angiogenesis in murine hepatocellular carcinoma cells.
Yoshiji H; Kuriyama S; Hicklin DJ; Huber J; Yoshii J; Miyamoto Y; Kawata M; Ikenaka Y; Nakatani T; Tsujinoue H; Fukui H
Hepatology; 1999 Nov; 30(5):1179-86. PubMed ID: 10534339
[TBL] [Abstract][Full Text] [Related]
49. Angiogenesis inhibition in cancer therapy: platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) and their receptors: biological functions and role in malignancy.
Appelmann I; Liersch R; Kessler T; Mesters RM; Berdel WE
Recent Results Cancer Res; 2010; 180():51-81. PubMed ID: 20033378
[TBL] [Abstract][Full Text] [Related]
50. Vitreous and aqueous concentrations of proangiogenic, antiangiogenic factors and other cytokines in diabetic retinopathy patients with macular edema: Implications for structural differences in macular profiles.
Patel JI; Tombran-Tink J; Hykin PG; Gregor ZJ; Cree IA
Exp Eye Res; 2006 May; 82(5):798-806. PubMed ID: 16324700
[TBL] [Abstract][Full Text] [Related]
51. Non-receptor protein-tyrosine kinases as molecular targets for antiangiogenic therapy (Review).
Kanda S; Miyata Y; Kanetake H; Smithgall TE
Int J Mol Med; 2007 Jul; 20(1):113-21. PubMed ID: 17549397
[TBL] [Abstract][Full Text] [Related]
52. Differential expression of the angiogenic factor genes vascular endothelial growth factor (VEGF) and endocrine gland-derived VEGF in normal and polycystic human ovaries.
Ferrara N; Frantz G; LeCouter J; Dillard-Telm L; Pham T; Draksharapu A; Giordano T; Peale F
Am J Pathol; 2003 Jun; 162(6):1881-93. PubMed ID: 12759245
[TBL] [Abstract][Full Text] [Related]
53. Modulation of in vivo growth of thyroid tumor-derived cell lines by sense and antisense vascular endothelial growth factor gene.
Belletti B; Ferraro P; Arra C; Baldassarre G; Bruni P; Staibano S; De Rosa G; Salvatore G; Fusco A; Persico MG; Viglietto G
Oncogene; 1999 Aug; 18(34):4860-9. PubMed ID: 10490819
[TBL] [Abstract][Full Text] [Related]
54. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis.
Hicklin DJ; Ellis LM
J Clin Oncol; 2005 Feb; 23(5):1011-27. PubMed ID: 15585754
[TBL] [Abstract][Full Text] [Related]
55. VGA1155, a novel binding antagonist of VEGF, inhibits angiogenesis in vitro and in vivo.
Ueda Y; Yamagishi T; Ikeya H; Hirayama N; Itokawa T; Aozuka Y; Samata K; Nakaike S; Tanaka M; Ono M; Saiki I
Anticancer Res; 2004; 24(5A):3009-17. PubMed ID: 15517909
[TBL] [Abstract][Full Text] [Related]
56. [Dynamic observation of vascular endothelial growth factor (VEGF)/VEGF-receptors expression in acute leukemia].
Wang C; Chen FY; Zhu JS; Xu YP; Han JY; Ouyang RR
Zhonghua Nei Ke Za Zhi; 2004 Nov; 43(11):845-8. PubMed ID: 15634546
[TBL] [Abstract][Full Text] [Related]
57. [VEGF as an angiogenic, neurotrophic, and neuroprotective factor].
Namiecińska M; Marciniak K; Nowak JZ
Postepy Hig Med Dosw (Online); 2005; 59():573-83. PubMed ID: 16407796
[TBL] [Abstract][Full Text] [Related]
58. High VEGF serum values are associated with locoregional spread of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Cigrovski Berković M; Čačev T; Catela Ivković T; Marout J; Ulamec M; Zjačić-Rotkvić V; Kapitanović S
Mol Cell Endocrinol; 2016 Apr; 425():61-8. PubMed ID: 26805636
[TBL] [Abstract][Full Text] [Related]
59. The role of vascular endothelial growth factor in pulmonary arterial hypertension. The angiogenesis paradox.
Voelkel NF; Gomez-Arroyo J
Am J Respir Cell Mol Biol; 2014 Oct; 51(4):474-84. PubMed ID: 24932885
[TBL] [Abstract][Full Text] [Related]
60. Polyproline-type helical-structured low-molecular weight heparin (LMWH)-taurocholate conjugate as a new angiogenesis inhibitor.
Lee E; Kim YS; Bae SM; Kim SK; Jin S; Chung SW; Lee M; Moon HT; Jeon OC; Park RW; Kim IS; Byun Y; Kim SY
Int J Cancer; 2009 Jun; 124(12):2755-65. PubMed ID: 19243020
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
